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Abstract
Nogo-A is a membrane protein of the central nervous system (CNS) restricting neurite growth and synaptic plasticity via two
extracellular domains: Nogo-66 and Nogo-A-D20. Receptors transducing Nogo-A-D20 signaling remained elusive so far.
Here we identify the G protein-coupled receptor (GPCR) sphingosine 1-phosphate receptor 2 (S1PR2) as a Nogo-A-D20-
specific receptor. Nogo-A-D20 binds S1PR2 on sites distinct from the pocket of the sphingolipid sphingosine 1-phosphate
(S1P) and signals via the G protein G13, the Rho GEF LARG, and RhoA. Deleting or blocking S1PR2 counteracts Nogo-A-D20-
and myelin-mediated inhibition of neurite outgrowth and cell spreading. Blockade of S1PR2 strongly enhances long-term
potentiation (LTP) in the hippocampus of wild-type but not Nogo-A2/2 mice, indicating a repressor function of the Nogo-A/
S1PR2 axis in synaptic plasticity. A similar increase in LTP was also observed in the motor cortex after S1PR2 blockade. We
propose a novel signaling model in which a GPCR functions as a receptor for two structurally unrelated ligands, a
membrane protein and a sphingolipid. Elucidating Nogo-A/S1PR2 signaling platforms will provide new insights into
regulation of synaptic plasticity.
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Introduction
Factors inhibiting nerve fiber growth substantially contribute to
the limited regenerative capacity of the adult central nervous
system (CNS) after injury. They play important roles in stabilizing
the complex wiring of the adult CNS of higher vertebrates and in
establishing neuronal pathways in the developing nervous system
[1,2]. One of the best-studied factors is the membrane protein
Nogo-A, which occurs in myelin and certain neurons, inhibiting
axonal regeneration and plasticity after CNS injury [3–5].
Neutralization of Nogo-A has been shown to enhance axonal
growth and compensatory sprouting in the adult spinal cord and
brain, as well as to improve functional recovery after CNS injury
[4,6]. Recent studies have shown novel important roles of Nogo-A
signaling in the repression of synaptic plasticity in mature neuronal
networks, indicating an inhibitory potential of Nogo-A far beyond
its well-studied restriction of axonal growth [1,7–11].
Nogo-A exerts its inhibitory effects via two distinct extracellular
domains: Nogo-66 (rat amino acid (aa) 1026–1091) and Nogo-A-
D20 (rat aa544–725; part of ‘‘Amino-Nogo’’) [2,12]. Nogo-66
induces growth inhibition via two membrane proteins, Nogo-66
receptor 1 (NgR1) [13], together with accessory proteins, and
paired immunoglobulin-like receptor B (PirB) [14]. By contrast,
the molecular identification and characterization of the receptor(s)
transducing signals from the inhibitory Nogo-A-D20 domain has
failed so far [2]. Nogo-A-D20 has been shown to partially mediate
its inhibitory activity by interfering with integrins, but proof of a
direct interaction has remained elusive [15]. Here we identified
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the G protein-coupled receptor (GPCR) sphingosine 1-phosphate
receptor 2 (S1PR2) as a functional receptor for the D20 domain of
Nogo-A.
S1PR2 belongs to the subfamily of five S1PRs [16]. S1PRs are
known to be activated by the low molecular weight (MW) lipid
ligand sphingosine 1-phosphate (S1P), which exerts diverse
receptor-specific effects on various cell types, including regulation
of apoptosis, cell motility and cytoskeleton dynamics [16]. In the
brain and spinal cord, S1P has been shown to regulate
angiogenesis and neurite outgrowth: activation of S1PR1 pro-
motes neurite outgrowth in vitro via Gi/o and Rac1, whereas
activation of S1PR2 leads to neurite retraction, involving Gi/o, Gq,
or G12/13 and the RhoA pathway [16–18].
In this study we demonstrate that Nogo-A-D20 binds S1PR2 via
extracellular receptor loops 2 and 3, which are distinct from the
previously described binding site of S1P [19]. Nogo-A-D20 signals
through the G protein G13, leukemia-associated Rho guanine
exchange factor (RhoGEF) LARG and RhoA. Deleting or
blocking S1PR2 counteracts Nogo-A-D20- and myelin-mediated
inhibition of neurite outgrowth and cell spreading. Acute S1PR2
blockade increases hippocampal and cortical long-term synaptic
plasticity similarly to Nogo-A neutralization. These results
strengthen the recently proposed physiological role of Nogo-A in
restricting synaptic plasticity to stabilize neuronal circuits [1,9].
Further, these data support the paradigm shift for GPCR signaling
from the classical ‘‘one ligand – one receptor’’ situation towards
more dynamic models [20,21].
Results
Nogo-A Binds to S1PR2
The GPCR S1PR2 was identified as a novel receptor candidate
of the Nogo-A-D20 domain using a yeast two-hybrid (Y2H) screen
of custom-made adult and fetal human brain libraries. In the adult
CNS, S1PR2 is mainly expressed in the grey matter (Figure 1).
Hippocampal pyramidal cells, cerebellar Purkinje cells, cortical
neurons and spinal motoneurons, as well as retinal ganglion cells
are S1PR2-positive (Figure 1A–1K). Importantly, S1PR2 is also
expressed in Nogo-A-D20-responsive cells in vitro including 3T3
fibroblasts and immature cerebellar granule neurons (Figure S1).
To validate the interaction of Nogo-A-D20 (Figure 2A) and
S1PR2, His-tagged Nogo-A-D20 was co-incubated with mem-
branes of S1PR2-overexpressing cells and subsequently immuno-
precipitated (Figure 2C). S1PR2 was specifically detected in
immunoprecipitation fractions (Figure 2C). Vice versa, His-tagged
Nogo-A-D20 could be specifically probed in S1PR2 immunopre-
cipitated fractions, suggesting that the two proteins interact in vitro
(Figure 2D). Co-immunoprecipitation experiments of Nogo-A or
S1PR2 from whole mouse brain protein extracts further demon-
strated that endogenous S1PR2 interacts with Nogo-A under
physiological conditions in vivo (Figure 2B). To determine the
binding affinity, binding of the entire D20-containing extracellular
N-terminal domain of Nogo-A (Nogo-A-ext; Figure 2A) to
biosensor-immobilized membrane preparations expressing func-
tional full length S1PR2 protein or non S1PR2-expressing control
membranes was monitored in real-time using Bio-Layer interfer-
ometry (OctetRED). Non-linear fitting revealed that Nogo-A-ext
binds to S1PR2 with an apparent equilibrium binding constant
(KD) of ,142 nM (Figure 2E). The binding affinity was not
influenced by the addition of S1P versus vehicle control (MeOH)
(KD MeOH,192 nM; KD S1P,202 nM; Figure 2F). For a mapping
of binding sites, individual extracellular domains (N-terminus and
extracellular loops [ECLs]) of S1PR2 were synthesized as peptides
and analyzed for binding to Nogo-A-D20 by microscale thermo-
phoresis (Figure 2G). Nogo-A-D20 was found to bind primarily to
ECL2 (KD,280 nM) and 3 (KD,350 nM), less strongly to ECL1
(KD,2 mM) and negligibly to the N-terminus of S1PR2
(KD,11 mM) (Figure 2G). Importantly, binding analysis of the
other bioactive domain of Nogo-A, Nogo-66, to S1PR2 extracel-
lular domains revealed only unspecific binding in the high
micromolar range (KD ECL1,46 mM; KD ECL2,7 mM; KD
ECL3,67 mM) or complete absence of binding (N-terminus)
(Figure 2H). Collectively, these data show that Nogo-A-D20 but
not Nogo-66 binds to specific extracellular domains of the GPCR
S1PR2.
S1PR2 Is Internalized upon Nogo-A-D20 Binding
We have shown previously that Nogo-A-D20 is internalized into
signaling endosomes upon binding, which results in RhoA
activation and growth cone collapse [22]. To investigate whether
S1PR2 is co-internalized upon Nogo-A-D20 treatment, cell surface
S1PR2 expression was analyzed by immunofluorescence using a
custom-made antibody (Figures 3A, S2B, and S2C). Cell surface
S1PR2 levels were reduced by ,64% (p,0.001) 30 min after
addition of Nogo-A-D20 (Figure 3B). To confirm this, plasma
membranes of 3T3 cells were prepared 15 and 30 min post-
incubation with Nogo-A-D20 and analyzed for S1PR2 levels by
immunoblotting (Figures 3C and S2A). We found that cell surface
S1PR2 levels were reduced by ,77% (p,0.01) and ,70% (p,
0.001) after 15 and 30 min incubation with Nogo-A-D20,
respectively, indicating that S1PR2 is internalized upon binding
to Nogo-A-D20 (Figure 3C). Pulse-chase experiments revealed that
the majority of internalized Nogo-A-D20 puncta colocalize with
S1PR2 as well as with the endosomal marker EEA1 at 15
and 30 min post-incubation with Nogo-A-D20 (Figure 3D).
Ubiquitination of GPCRs is a critical post-translational modifica-
tion, which is often dispensable for initial receptor endocytosis
but important for endosomal trafficking to proteasome/lysosomal
degradation pathways [23,24]. S1P has been shown to cause
S1PR1 monoubiquitination and, in higher concentrations,
polyubiquitination, resulting in subsequent GPCR recycling
to the membrane or complete degradation, respectively [25].
Author Summary
Recent studies have demonstrated an important role of
Nogo-A signaling in the repression of structural and
synaptic plasticity in mature neuronal networks of the
central nervous system. These insights extended our
understanding of Nogo-A’s inhibitory function far beyond
its well-studied role as axonal-growth inhibitor. Repression
is mediated via two different Nogo-A extracellular
domains: Nogo-66 and Nogo-A-D20. Here, we identify
the G-protein coupled receptor S1PR2 as a high-affinity
receptor for Nogo-A-D20 and demonstrate that S1PR2
binds this domain with sites different from the recently
proposed S1P binding pocket. Interfering with S1PR2
activity, either pharmacologically or genetically, prevented
Nogo-A-D20-mediated inhibitory effects. Similar results
were obtained when we blocked G13, LARG, and RhoA,
components of the downstream signaling pathway. These
findings revealed a strong increase in hippocampal and
cortical synaptic plasticity when acutely interfering with
Nogo-A/S1PR2 signaling, similar to previous results ob-
tained by blocking Nogo-A. We thus provide a novel
biological concept of multi-ligand GPCR signaling in which
this sphingolipid-activated GPCR is also bound and
activated by the high molecular weight membrane protein
Nogo-A.
S1PR2 Is a Receptor for Nogo-A
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Figure 1. Localization of S1PR2 by immunohistochemistry in the adult mouse CNS. (A) S1PR2 expression in the hippocampus. CA, cornu
ammonis; DG, dentate gyrus. (B) Magnification of the boxed region of CA1 depicted in (A). (C) S1PR2 expression in the cerebellum. GCL, granule cell
layer; ML, molecular layer; PCL, Purkinje cell layer. (D) Magnification of the boxed region depicted in (C). (E) S1PR2 expression in the motor cortex. (F)
S1PR2 Is a Receptor for Nogo-A
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S1PR2-ubiquitin conjugates were not detected upon internaliza-
tion of Nogo-A-D20 as opposed to S1P (Figure 3E), indicating that
Nogo-A-D20 signaling is not permanently terminated in the
lysosomal degradation pathway [23–25]. These results suggest that
S1PR2 is rapidly co-internalized with Nogo-A-D20 into early
endosomes upon binding, which is known to be a key step for
Nogo-A-D20-mediated growth inhibition [22].
S1PR2 Mediates Nogo-A-D20-Induced Inhibition of Cell
Spreading and Neurite Outgrowth
Nogo-A-D20 exerts strong inhibitory effects on growth and
adhesion of different neuronal cell types and, unlike Nogo-66, also
on non-neuronal cells such as 3T3 fibroblasts, which are devoid of
NgR1 expression [12]. To determine the functional role of S1PR2
for Nogo-A-D20-mediated effects in vitro, the well-characterized
S1PR2 blocker JTE-013 [26] was tested for its ability to reverse
Nogo-A-D20-mediated inhibition of cell spreading. Treatment of
3T3 cells with JTE-013 significantly counteracted Nogo-A-D20-
mediated cell spreading inhibition, resulting in an ,24% increase
of spread cells when compared to vehicle (DMSO) (p,0.05)
(Figure 4A and 4B). Similarly, on myelin, cell spreading was
increased by ,56% (p,0.001) (Figure 4A and 4B). These effects
were dose-dependent (Figure S3A) and S1PR subtype-specific
(Figure S3B): blockade of S1PR1 with W146, S1PR1 and 3 with
VPC-23019, S1PR1, 3, 4, and 5 with FTY-720 or S1PR5 with a
function-blocking antibody [27] had no effect on Nogo-A-D20-
mediated cell spreading inhibition (Figure S3B). In addition, no
synergistic effect was observed by combining JTE-013 with any of
these blocking agents (Figure S3C), suggesting that solely S1PR2 is
responsible for Nogo-A-D20-mediated effects in 3T3 cells. To
underline the functional importance of S1PR2, its expression was
retrovirally silenced in 3T3 cells (sh-S1pr2; Figure S4A and S4B).
Knockdown of S1PR2 resulted in a very strong increase of cell
spreading on a Nogo-A-D20 (,51%; p,0.001) or myelin (,44%;
p,0.001) substrate when compared to the control vector (sh-Vec)
(Figure 4C and 4D). Similarly, primary mouse embryonic
fibroblasts (MEFs) isolated from S1PR22/2 mice [28] were
significantly less inhibited by Nogo-A-D20 (,41%; p,0.01) or
myelin (,36%; p,0.01) when compared to wild-type (WT) MEFs
(Figure 4E and 4F).
To investigate the functional importance of S1PR2 in Nogo-A-
D20-mediated neurite outgrowth inhibition, we focused on
postnatal day (P) 5–8 cerebellar granule neurons that express
S1PR2 (Figure S1B). Pharmacological blockade of S1PR2 using
JTE-013 led to a ,39% (p,0.01) and ,44% (p,0.05) increase in
outgrowth on a Nogo-A-D20 and myelin substrate, respectively
(Figure 4G and 4H). Similarly, knockout of S1PR2 also increased
neurite outgrowth by ,51% (p,0.001) and ,69% (p,0.001) on a
Nogo-A-D20 and myelin substrate, respectively (Figure 4I and 4J).
Together, these results provide strong evidence that S1PR2 acts as
a functional receptor for Nogo-A-D20. Importantly, application of
JTE-013 had no effect on a growth-inhibitory Nogo-66 or
Aggrecan substrate (Figure S5).
Nogo-A-D20 Signals through G13, LARG, and RhoA
The G proteins Gq, G12, and G13 were shown to interact with
S1PR2 and to activate the small GTPase RhoA [16,29]. To
determine whether Gq, G12, or G13 are implicated in Nogo-A-
D20-mediated cell spreading inhibition, we transfected small
interfering RNAs (siRNAs) targeting the mRNAs of the G proteins
(Figure S4C and S4D). Downregulation of G13 but not of Gq or
G12 fully rescued cell spreading from ,63% to ,134% on Nogo-
A-D20 when compared to the siRNA control (p,0.01) (Figure 5A).
No cumulative effect was observed by co-application of JTE-013,
suggesting that G13 is a key regulator of Nogo-A-D20-mediated
effects downstream of S1PR2 (Figure 5A). Accordingly, inhibition
of the Rac1-coupled Gi/o protein [16] with Pertussis toxin (PTX)
did not have any effect on Nogo-A-D20-mediated cell spreading
inhibition (Figure 5A). To assess whether G13 is also involved in
Nogo-A-D20-mediated inhibition of neurite outgrowth, G13 was
silenced in E19 rat cortical neurons using specific siRNAs (Figure
S4E and S4F). Knockdown of G13 but not of G12 specifically
rescued outgrowth from ,68% to ,87% on Nogo-A-D20 when
compared to the siRNA control (p,0.05) (Figure 5B). Taken
together, these results demonstrate that G13 is required for Nogo-
A-D20-mediated inhibition of cell spreading and neurite out-
growth in vitro.
S1PR2 has been shown to couple via G12/13 to the RhoGEF
LARG to mediate various RhoA-dependent cellular effects [30].
siRNA-mediated downregulation of LARG fully rescued cell
spreading from ,63% to ,103% on Nogo-A-D20 when
compared to the siRNA control (p,0.01) (Figures 5A, S4C, and
S4G). This is in line with LARG-mediated activation of RhoA
reported for other repulsive cues such as S1P (via S1PR2 [30]),
semaphorin4D (via PlexinB1 [31]), and repulsive guidance
molecule RGMa (via Unc5b [32]).
To test whether Nogo-A-D20-induced activation of RhoA
[22,33] is S1PR2-dependent, endogenous RhoA activity was
measured upon blockade or silencing of S1PR2 in 3T3 cells
(Figure 5C–5F). Under control conditions, a ,2-fold increase in
RhoA activation was observed after 20 min of incubation with
Nogo-A-D20 (Figure 5C and 5D). Upon application of JTE-013
(Figure 5C and 5E) or silencing of S1PR2 (Figure 5D and 5F),
RhoA activation was fully suppressed (p,0.05). These results
suggest that S1PR2 is required for Nogo-A-D20-induced RhoA
activation, most probably via a G13-LARG signaling pathway.
Nogo-A-D20-Mediated Inhibition Is Modulated by
Exogenous S1P
To determine possible functional interactions of Nogo-A-D20
and S1P at the level of S1PR2, we first investigated whether Nogo-
A-D20 itself modulates S1P production. Extra- (EC) and
intracellular (IC) S1P levels were quantified in 3T3 and cerebellar
granule neuron cultures after a 30 and 60 min stimulation with
Nogo-A-D20 (Figure 5G and 5H). No significant changes
compared to control levels were detected, indicating that Nogo-
A-D20 had no influence on S1P production under our experi-
mental conditions (Figure 5G and 5H).
We then addressed the role of endogenous S1P in Nogo-A-D20-
mediated inhibitory effects. Pharmacological blockade of the S1P-
producing enzymes sphingosine kinase (SphK) 1 and 2 using D,L-
threo-dihydrosphingosine (DHS) [34,35] had no effect on Nogo-A-
D20-mediated inhibition of cell spreading, suggesting that SphKs
are not downstream elements of Nogo-A-D20-induced inhibition
(Figure 5I). To confirm this result, MEFs isolated from SphK12/2
or SphK22/2 mice [36] were plated on a Nogo-A-D20 substrate.
Similarly to SphK blockade, no differences in cell spreading
inhibition were observed (Figure 5I).
Magnification of the boxed region depicted in (E). (G,H) S1PR2 expression in motoneuron cell bodies (arrows) and bIII-Tubulin-positive fibers
(arrowheads) in the spinal cord. (I,J,K) S1PR2 expression in bIII-Tubulin-positive axons bundles (arrowheads) and cell bodies (arrows) of retinal
ganglion cells. Scale bars: (A) 300 mm; (B) 30 mm; (C) 200 mm; (D) 15 mm; (E) 90 mm; (F) 30 mm; (G,H) 20 mm; (I–K) 15 mm.
doi:10.1371/journal.pbio.1001763.g001
S1PR2 Is a Receptor for Nogo-A
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Figure 2. Nogo-A binds to S1PR2. (A) Schematic structure of Nogo-A showing the inhibitory domains Nogo-A-D20 (D20, orange), Nogo-66 (blue),
and Nogo-A-ext. Transmembrane domains are indicated in dark grey. RHD, reticulon homology domain. (B) Nogo-A (,200 kDa) co-
immunoprecipitated with S1PR2 (,40 kDa) and vice-versa in WT but not Nogo-A2/2 or S1PR22/2 brain extracts (BE). If specified, the following
controls were used in WT BE instead of the IP antibody to confirm the specificity of the interaction: IgG, control antibody; Ctrl R, resin only control;
qAbR, quenched antibody (Ab) resin control. Input loading control: b-Actin (,42 kDa). (C) S1PR2 immunoprecipitated with His-tagged D20 but not
heat-inactivated (hi) D20 in S1PR2-overexpressing membranes. Input loading control: S1PR2. (D) His-tagged D20 but not hi D20 immunoprecipitated
with S1PR2 in S1PR2-overexpressing membranes. Input loading control: S1PR2. (E) Nogo-A-ext bound specifically to biosensor-immobilized S1PR2-
overexpressing versus control membranes (KD,142 nM). A Scatchard plot analysis is shown on the right. (F) 1 mM S1P does not modulate the
interaction between Nogo-A-ext and S1PR2 when compared to the methanol (MeOH) vehicle control (MeOH, KD,192 nM; S1P, KD,202 nM). A
Scatchard plot analysis is shown on the right. (G) Microscale thermophoresis binding analysis of D20 to S1PR2 extracellular domains: ECL2
(KD,280 nM), ECL3 (KD,350 nM), ECL1 (KD,1.7 mM), and N-terminus (KD,11 mM). Scrambled ECL1 (ECL1-scr) was used as control (KD,17 mM).
Arrows indicate the identified D20-binding loops in S1PR2. (H) Nogo-66 binding to S1PR2 extracellular domains is unspecific: ECL2 (KD,7 mM), ECL1
(KD,46 mM), ECL3 (KD,67 mM). No binding to the N-Terminus or to ECL1-scr is observed.
doi:10.1371/journal.pbio.1001763.g002
S1PR2 Is a Receptor for Nogo-A
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Because S1P is found in fetal bovine serum (FBS)-containing
medium [37] used in our experimental conditions, we investigated if
serum-derived S1P modulates Nogo-A-D20-mediated inhibition.
For this purpose, extracellular S1P was scavenged using the
monoclonal anti-S1P antibody Sphingomab [38]. Cell spreading
analysis revealed that Nogo-A-D20-induced inhibition was alleviated
by ,28% (p,0.05) in the presence of the anti-S1P antibody when
compared to the anti-BrdU control (Figure 5J). To exclude that
disinhibition of Nogo-A-D20 signaling by blocking or silencing
S1PR2 is mediated by an increased activation of Rac1-coupled
S1PR1 through serum-derived S1P, anti-S1P was applied together
with JTE-013. No differences could be observed between anti-S1P-
and anti-BrdU-treated cells in the presence of JTE-013 (Figure 5J).
Together, these results suggest that S1PR2-mediated inhibition by
Nogo-A-D20 occurs independently of S1P but that S1P can
modulate Nogo-A-D20-mediated effects. Indeed, addition of S1P
to cells resulted in an ,31% (p,0.001) and ,28% (p,0.001)
decrease in cell spreading inhibition on a control and Nogo-A-D20
substrate, respectively, when compared to the MeOH + DMSO
control (Figure 5K). These results point to a modulatory function of
S1P in Nogo-A-D20-mediated inhibition of cell spreading, presum-
ably by independently activating RhoA-coupled cell surface S1PRs,
e.g., S1PR2. Concordantly, S1P has been previously described to
modulate cell adhesion and growth of different cell types [18,27,39].
To test this hypothesis, JTE-013 was co-applied with S1P. S1P-
induced inhibition of cell spreading could be significantly reversed on
a control and Nogo-A-D20 substrate in the presence of JTE-013 (p,
0.001) (Figure 5K). Together, these results indicate that S1P can
modulate Nogo-A-D20-mediated cell spreading inhibition via
S1PR2. However, they also suggest that Nogo-A-D20 acts indepen-
dently of SphK or S1P.
Nogo-A Restricts Long-Term Potentiation via S1PR2 in
the Hippocampus and Motor Cortex
Growing evidence suggests that Nogo-A plays an important role
in restricting synaptic plasticity [6,9,11]. S1PR2 is expressed in
Figure 3. S1PR2 is internalized upon Nogo-A-D20 binding. (A) Representative confocal micrographs of 3T3 cells stained alive (Non-perm) or
fixed (Perm) for S1PR2 before (control) and 30 min after D20 treatment at 37uC. (B) Mean fluorescence intensity quantification of the cell surface
staining shown in (A). (C) Addition of D20 downregulates cell surface S1PR2 in 3T3 plasma membranes (PM): immunoblot and relative quantification
thereof. Loading control: b-Actin. (D) Representative confocal micrographs of 3T3 cells incubated with 1 mM HA-tagged D20 for 1 h at 4uC (pulse),
which were then subsequently chased for 15 and 30 min at 37uC. Cells were stained with an anti-HA (D20), S1PR2, or EEA1 antibody (early
endosomes). Arrows indicate cell surface-bound D20 (top panel) or colocalization of D20 and S1PR2 in early endosomes (middle and bottom panel).
The inset panel shows an enlarged view of the boxed region. (E) Western blot analysis of ubiquitinated and non-ubiquitinated protein fractions of 3T3
cells 30 min after D20 or S1P treatment. Data shown are means 6 SEM (n=3–6 experiments; **p,0.01, ***p,0.001). Scale bars: (A,D) 50 mm.
doi:10.1371/journal.pbio.1001763.g003
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Figure 4. S1PR2 mediates Nogo-A-D20- and myelin-induced inhibition of cell spreading and neurite outgrowth. (A,C) Representative
pictures of 3T3 fibroblasts treated with JTE-013 or vehicle (DMSO) (A), or stably carrying a S1pr2 shRNA (sh-S1pr2) or empty vector (sh-Vec) construct
(C) and plated on control, Nogo-A-D20 or myelin substrates. (B,D) Cell spreading quantification of (A) and (C). (E) Representative pictures of MEFs
isolated from WT or S1PR22/2 mice and plated on control, Nogo-A- D20, or myelin substrates. (F) Cell spreading quantification of (E). Cells were
stained with Alexa488-conjugated Phalloidin in (A, C, and E). (G,I) Representative pictures of P5–8 cerebellar granule neurons treated with JTE-013 or
DMSO (G), or isolated from S1PR22/2 or WT mice (I) and plated on PLL (ctrl), Nogo-A-D20 or myelin substrates. (H,J) Normalized mean neurite length
per cell quantification of (G) and (I). Neurons were stained with bIII-Tubulin in (G) and (I). Data shown are means 6 SEM (n= 3–6 experiments; *p,
0.05, **p,0.01, ***p,0.001). Scale bars: 50 mM.
doi:10.1371/journal.pbio.1001763.g004
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Figure 5. Nogo-A-D20 inhibition is mediated via the G13-LARG-RhoA signaling axis and can be modulated by exogenous S1P. (A)
3T3 cells transfected with siRNAs against G12, G13, Gq, or Larg, or control (ctrl) siRNA were replated on a Nogo-A-D20 substrate and assessed for cell
spreading. Gi/o was blocked with Pertussis Toxin (PTX) for which saline was used as control. JTE-013 was co-applied to G13-siRNA-treated cells to
investigate a cumulative effect. (B) Transfection of DIV4 E19 cortical neurons with siRNA against G13 but not G12 similarly rescued Nogo-A-D20-
induced neurite outgrowth inhibition. (C,D) Nogo-A-D20-induced RhoA activation was assessed in JTE-013- versus DMSO-treated cells (C) or in cells
carrying a stable knockdown of S1PR2 (sh-S1pr2) versus control vector (sh-Vec) (D). (E,F) Relative quantification of (C) and (D), respectively. (G,H)
Competitive ELISA quantifications of extra- (EC) and intracellular (IC) S1P levels in 3T3 cells (G) and cerebellar granule neurons (H) before and after 30
and 60 min incubation with Nogo-A-D20. (I) Quantification of Nogo-A-D20-mediated cell spreading inhibition in the presence of the SphK-specific
blocker D,L-threo-dihydrosphingosine (DHS) or in SphK12/2 or SphK22/2 MEFs. (J,K) 3T3 cells were plated on a Nogo-A-D20 substrate in the presence
of the function blocking anti-S1P antibody Sphingomab (J) or of exogenous S1P (K) and assessed for cell spreading. Co-application of JTE-013
significantly reversed the modulatory effects obtained by S1P (K) but not anti-S1P (J). Anti-BrdU antibody or methanol was used as control in (J) and
(K). Data shown are means 6 SEM (n= 3–6 experiments; *p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pbio.1001763.g005
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CA1 and CA3 pyramidal neurons (Figure 1A and 1B). In order to
investigate the role of the Nogo-A/S1PR2 axis in long-term
potentiation (LTP), hippocampal slices of WT and Nogo-A2/2
mice were tested for LTP after acute blockade of S1PR2 using
JTE-013. In WT slices, application of JTE-013 resulted in a
significant increase in LTP compared with vehicle (DMSO)
(,22%; p,0.05) (Figure 6A). In contrast, no differences in LTP
were detected in Nogo-A2/2 slices treated with JTE-013 or
vehicle, suggesting that Nogo-A is required for S1PR2-mediated
effects on LTP (Figure 6B). No differences in input-output (I/O)
curves and paired-pulse facilitation (PPF) could be observed by
application of JTE-013, suggesting that S1PR2 blockade does not
alter baseline synaptic transmission or the properties of presynap-
tic terminals (Figure 6C–6F). In order to confirm the specificity of
S1PR2, LTP was measured after blockade of the remaining S1PRs
(Figure S6A and S6B). No differences in LTP and PPF could be
observed upon application of VPC-23019 or FTY-720, empha-
sizing the specificity of a functional Nogo-A/S1PR2 interaction
(Figure S6A–S6C). Next, we investigated LTP, baseline synaptic
transmission as well as PPF in S1PR22/2 versus WT hippocampal
slices. No significant changes in LTP, I/O, or PPF could be
observed in S1PR22/2 versus WT mice (Figure S6D–S6F) as
opposed to acute neutralization of S1PR2. These results mirror
those obtained in Nogo-A KO [7] or NgR1 KO [8] mice and
suggest that there is a strong drive for genetic compensation in this
functionally very important system. [11].
Next, the outcome of a combined neutralization of the ligand
Nogo-A by the function-blocking anti-Nogo-A antibody 11c7 [12]
and of the receptor S1PR2 by JTE-013 was analyzed. A synergistic
effect of the combined treatment as compared to either treatment
alone would indicate that additional molecules, e.g., S1P are
involved in S1PR2-mediated LTP restriction. A similar increase in
LTP for all treated groups when compared to the IgG1 + DMSO
control with no difference between the groups was observed
(Figure 6G). To assess the relative contribution of the Nogo-A
receptors NgR1 and S1PR2 onto Nogo-A-mediated restriction of
synaptic plasticity, we simultaneously blocked both receptors. No
significant difference could be observed between application of
JTE-013 alone versus the combined application of JTE-013 and of
the function-blocking anti-NgR1 antibody (Figure 6H).
Finally, we investigated the effect of S1PR2 blockade on long-
term depression (LTD) in the hippocampus. In line with the results
obtained after acute Nogo-A neutralization [7], JTE-013 applica-
tion did neither modulate LTD induction nor maintenance
compared with control conditions (Figure S6G).
Recent data indicate that Nogo-A also restricts synaptic
plasticity in the primary motor cortex [11]. LTP saturation in
this region was also significantly increased in JTE-013 versus
DMSO-treated slices (,39%; p,0.001) (Figure 6I). No differences
in the I/O curves were observed after S1PR2 blockade, indicating
that the JTE-013-mediated increase in synaptic plasticity was not
due to alterations in baseline synaptic transmission (Figure 6J).
Together, these results show that Nogo-A represses synaptic
plasticity in the hippocampus and motor cortex via S1PR2.
Discussion
Two distinct domains of Nogo-A can induce growth inhibition:
Nogo-A-D20 and Nogo-66. Here, we identified the GPCR S1PR2
as the first functional receptor for the inhibitory D20 domain of
Nogo-A. S1PR2 fulfills essential key criteria to be a Nogo-A-D20-
specific receptor: (i) Expression in the CNS as well as in non-
neuronal Nogo-A-D20-responsive cells; (ii) high-affinity binding to
Nogo-A-D20; (iii) prerequisite for Nogo-A-D20-induced inhibition
of cell spreading and neurite outgrowth; (iv) Nogo-A-D20-induced
activation of RhoA; (v) restriction of hippocampal and cortical
synaptic plasticity.
S1PR2 Is a Receptor for a Lipid and a Protein Ligand
Until very recently, GPCRs were generally thought to be
activated by physical and low MW chemical stimuli [40].
However, a few adhesion GPCRs were found to also bind to
membrane-bound and matrix ligands via an extended N-terminal
region [41,42]. Many of these receptors such as EGF-containing
CD97, the first GPCR shown to bind to the cellular ligand decay
accelerating factor, are predominantly expressed by immune cells
[43]. To our knowledge, Nogo-A is the first mammalian
membrane protein shown to bind to and signal through a non-
orphan GPCR of the rhodopsin-like family. In contrast to
adhesion GPCRs, S1PR2 does not bind Nogo-A-D20 via its N-
terminal domain.
The recent characterization of the crystal structure of S1PR1
provided substantial structural information on its activation by
S1P [19]. Access of the ligand to the binding pocket from the
extracellular space is occluded by the N-terminus and the ECLs,
and may be gained from within the membrane [19]. Our data
provide strong evidence that Nogo-A-D20 primarily interacts with
ECL2 and ECL3 of S1PR2, suggesting a different mechanism of
activation compared to S1P. Our results also suggest that S1PR2-
mediated inhibition by Nogo-A-D20 does not require S1P but can
be exogenously modulated by the latter. Although binding of
Nogo-A-D20 to S1PR2 does not require S1P, modulation of
receptor-specific physiological outputs by binding of the bioactive
lipid to its pocket within the membrane may further expand the
signaling repertoire of S1PR2. It may also enable fine-tuned
cellular responses depending on the ratio of ligands present under
given conditions, as recently suggested for the receptor for
advanced glycation endproducts (RAGE) [44]. Future biochemical
and structural studies will be necessary to address this and show
how binding is transferred into ligand-specific G-protein-depen-
dent signaling. Detailed investigations will also need to determine
whether the presence of additional receptors, i.e. NgR1, affects the
binding properties of Nogo-A-D20 to S1PR2 as described for other
multi-receptor systems, e.g., the viral surface glycoprotein gp120 to
CD4 and the GPCR co-receptor CCR5 [45]. We could show that
Nogo-A interacts with S1PR2 in trans. However, interaction at the
surface of the same cell in cis might also be possible, similar to what
has been proposed for the Nogo-A–NgR1 interaction in Purkinje
cells recently [46]. Yet, such mechanisms have not been proven
and their existence needs to be investigated in detail.
Multi-ligand/Multi-receptor Cross-Talk
The classic ‘‘one ligand–one receptor’’ paradigm has recently
been challenged by an increasing number of multi-ligand/multi-
receptor interactions, which could be identified in different
biological systems, adding another level of complexity for fine-
tuning of cellular responses [20]. Examples include neurotrophin
receptors, Wnt receptors, and receptors for axonal guidance
molecules such as plexins and neuropilins [20]. We propose that
the D20 domain of Nogo-A binds to S1PR2 and the Nogo-66 loop
to NgR1 and/or PirB, resulting in the formation of a multi-site/
multi-ligand receptor complex. NgR1 and PirB can also interact
with ligands other than Nogo-A, thereby increasing the dynamics
of signal transduction [6,9]. Additional Nogo-A co-receptors and
downstream signaling components potentially located within or
attached to these multi-receptor complexes might further amplify
Nogo-A-mediated inhibitory effects. It was recently demonstrated
that canonical GPCR signaling also occurs from endosomes for,
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Figure 6. Blockade of S1PR2 phenocopies the increase in hippocampal and cortical LTP observed upon Nogo-A neutralization. (A,B)
Hippocampal WT (A) and Nogo-A2/2 (B) slices were treated with JTE-013 or vehicle (DMSO) (WTDMSO: n=8; Nogo-A
2/2
DMSO: n= 10; WTJTE-013: n=11;
Nogo-A2/2JTE-013: n= 9). 60 min after theta-burst stimulation (arrow), a significant difference in LTP could be observed between JTE-013 and DMSO
treatment in WT (A) but not Nogo-A2/2 (B) slices. (C,D) Input-output strength revealed no differences in JTE-013- versus DMSO-treated slices of WT
(C) and Nogo-A2/2 (D) mice (WTDMSO: n=6; Nogo-A
2/2
DMSO: n= 6; WTJTE-013: n= 7; Nogo-A
2/2
JTE-013: n= 6). (E,F) PPF revealed no alterations in
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e.g., the Wnt receptor Frizzled [47] and the b2-adrenoceptor [48].
Along this line, the Nogo-A-D20/S1PR2 complex is co-internal-
ized into endosomes, from which signaling may be sustained.
Currently, the concerted action and downstream trafficking of all
these receptor components is still poorly understood, in particular
in vivo. Future studies will need to assess whether all Nogo-A
(co-)receptors are found within the same complex or in different
membrane microdomains, and how the receptor composition
varies between different cell types, developmental stages, and
pathophysiological conditions.
Interfering with Nogo-A/S1PR2 Signaling Increases
Synaptic Plasticity
Nogo-A stabilizes neuronal networks by restricting CNS
plasticity [2,9]. Acute neutralization of Nogo-A or NgR1 in
hippocampal slices was shown to induce an increase in LTP at
CA3-CA1 synapses [7]. On the other hand, conventional
knockouts of Nogo-A, PirB, or NgR1 do not show significant
modulations in LTP, presumably due to compensatory mecha-
nisms [7,8,10,11,49]. This is well in line with the lack of LTP
modulation observed in S1PR22/2 mice. A novel transgenic rat
model in which Nogo-A expression was silenced but not
completely ablated by using a synthetic anti-Nogo-A microRNA
leaving the genomic locus intact showed a significant increase in
LTP in the hippocampus as well as in the motor cortex [11]. This
underlines the strong drive for genetic compensation after
complete ablation of components within this functionally very
important system. Our present findings revealed an increase in
hippocampal and cortical LTP when acutely interfering with
S1PR2 signaling by JTE-013. Notably, no JTE-013-mediated
increase in hippocampal LTP was observed in Nogo-A2/2 mice,
underlining the plasticity-restricting role of Nogo-A/S1PR2
signaling independently of S1P. Indeed, CA3–CA1 LTP was
shown to be independent of SphK/S1P receptor signaling [50].
Interestingly, the blockade of both Nogo-A receptors NgR1 and
S1PR2 does not show an additive effect on LTP potentiation,
suggesting that both receptor-evoked responses induced by
different domains of Nogo-A converge onto the same signaling
pathways. However, detailed mechanisms and kinetics by which
Nogo-A/S1PR2-NgR1 modify synaptic plasticity remain to be
analyzed.
Conclusion
Our finding that the GPCR S1PR2 binds two structurally
unrelated molecules, a low MW sphingolipid and the high MW
membrane protein Nogo-A, by distinct sites contributes to and
extends the paradigm shift from a classical linear model of GPCR
signaling towards a more dynamic model with shared components
and intramolecular cross talks [51,52]. It will be important to
understand to which extent S1P affects signaling induced by Nogo-
A and vice-versa. Detailed high-resolution structural character-
ization of the receptor in complex with S1P, Nogo-A, or both will
be required to unravel the mechanistic properties of these two
signaling systems. Furthermore, the cell-specific interplay of
S1PR2 with known receptors and co-receptors for Nogo-A needs
to be determined in detail with regard to their corresponding
physiological effects. This information will be the basis for the
design of novel molecular tools to better understand the roles of
Nogo-A/S1PR2 signaling for CNS plasticity and repair.
Materials and Methods
Animals
All animal experiments were performed with the approval of
and in strict accordance with the guidelines of the Zurich
Cantonal Veterinary Office. All efforts were made to minimize
animal suffering and to reduce the number of animals required.
S1pr22/2 (B6.129S6-S1pr2tm1Rlp) mice were produced by
targeted mutagenesis as described previously [28] and backcrossed
to C57BL/6 background.
Ensembl Accession Numbers
Accession numbers mentioned in this paper from the Ensembl
Genome Browser (www.ensembl.org) are: Gna12, EN-
SMUSG00000000149; Gna13, ENSMUSG00000020611; Larg,
ENSMUSG00000059495; RhoA, ENSMUSG00000007815; Rtn4,
ENSMUSG00000020458, ENSRNOG00000004621; S1pr2, EN-
SMUSG00000043895.
Yeast Two-Hybrid Screen
The Nogo-A-D20 recombinant protein fused to the activation
domain of the GAL4 transcription factor was used as bait to screen
for interacting proteins from cDNAs from adult and fetal brain
libraries (Clontech) using the yeast two-hybrid (Y2H) method as
described previously [53]. Briefly, the cDNA encoding bait
fragment was generated by PCR, cloned into pDONR201, and
transferred into GATEWAY (Invitrogen)-compatible versions of
pGBT9 by the LR reaction. Yeast strain CG1945 (Clontech) was
transformed with the resulting vector. cDNA libraries were
transformed into Y187 strain (Clontech). Bait- and prey-expressing
yeasts were mated in YPDA in the presence of 10% polyethylene
glycol 6000. Medium was changed to selective medium (synthetic
dextrose) lacking Leu, Trp, and His with the following additives:
0.5% penicillin/streptomycin (50 mg/ml, Invitrogen), 50 mm 4-
methylumbelliferyl-a-d-galactoside (Sigma), and varying concen-
trations of 3-amino-1, 2, 4-triazole (3-AT, Sigma). Different
concentrations of 3-AT were tested in pre-screens, varying from 0–
60 mM. 60 mM 3-AT produced ,20% hits; 130 mM 3-AT was
used in the main screen, resulting in ,0.5% strong bait-prey
interactions. Mating efficiency was determined by plating of cells
on selective agar plates. The cell suspension was aliquoted into
microtiter plates (96 wells/plate, flat bottom, 200 ml/well) and
incubated for 3–7 days. Positive clones were screened by
determining fluorescence on a SpectraFluor fluorometer (Tecan)
at 465 nm (excitation at 360 nm). Wells that displayed fluores-
cence above background were identified and automatically
collected by a Tecan Genesis 200 robot. Selected cells were
passaged twice and transferred to an agar plate before PCR
amplification of the library inserts. After DNA sequencing and
sequence blasting, all bait-prey interactions were assessed for
JTE-013- versus DMSO-treated slices of WT (E) and Nogo-A2/2 (F) mice (WTDMSO: n=7; Nogo-A
2/2
DMSO: n=6; WTJTE-013: n=5; Nogo-A
2/2
JTE-013: n= 6).
(G) LTP was measured upon simultaneous neutralization of S1PR2 using JTE-013 and of Nogo-A using 11c7 (IgG1 + DMSO: n= 7; IgG1 + JTE-013: n= 6;
11c7 + DMSO: n= 8; 11c7 + JTE-013: n= 6). (H) LTP was measured upon simultaneous neutralization of S1PR2 using JTE-013 and of NgR1 using anti-
NgR1 (DMSO: n=7; JTE-013: n= 9; anti-NgR1 + JTE-013: n= 8). (I) Rat motor forelimb area brain slices were treated with JTE-013 (n=7) or DMSO
(n=8). Peak amplitudes were significantly larger in JTE-013- versus DMSO-treated slices upon repeated inductions of LTP (multiple arrows). (J) Input-
output strength revealed no differences in JTE-013- (n=8) versus DMSO-treated (n=12) cortical slices. Insets show representative traces. Data shown
are means 6 SEM (*p,0.05). n indicates the number of mice used.
doi:10.1371/journal.pbio.1001763.g006
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intrinsic prey promiscuities by comparison with in house databases
containing prey information on binding frequencies obtained from
previous studies [53]. Ingenuity Pathway Analysis (IPA, Ingenuity
Systems) was subsequently used to identify if interaction partners
signal via RhoA.
Tissue Preparation and Cell Culture
Total myelin protein extracts were prepared from the brains
and spinal cords of adult Wistar rats as described previously [12].
Swiss 3T3 (ATCC), NIH 3T3 cells (ATCC), and HEK293T cells
(ATCC) were maintained in DMEM containing 10% neonatal calf
serum (Invitrogen). Postnatal (P5–8) cerebellar granule neurons
were prepared as described previously [12]. Embryonic day (E) 19
rat cortical neurons were prepared as described previously [8].
Primary MEFs were isolated and immortalized as described
previously [54]. Each primary fibroblast culture was isolated from
a single E9.5 S1pr22/2 or WT littermate mouse.
siRNA, shRNA, and Recombinant Fusion Proteins
S1PR2 (ENST00000317726) was PCR-amplified from human
blood RNA, cloned into the EcoRI/Xho sites of the pcDNA5
vector (Invitrogen) and fully sequenced. The mouse sequences of
the siRNAs used are G12 (Gna12): GCGACACCAUCUUCGACAACAU,
G13 (Gna13): CUGGGUGAGUCUGUAAAGUAUU, Gq (Gnaq): GCUGGU-
GUAUCAGAACAUC, and Larg: sc-41801 (Santa Cruz Biotechnology).
The rat sequences are G12 ON-TARGETplus siRNA SMART-
pool L-088001-02-0005 (Thermo Scientific) and G13 ON-TAR-
GETplus siRNA SMARTpool L-086608-02-0005 (Thermo Sci-
entific). A scrambled siRNA sequence was used as control
(Dharmacon). NIH 3T3 cells were transfected using Lipofecta-
mine LTX according to the manufacturer’s instructions (Invitro-
gen). E19 cortical neurons were transfected at days in vitro (DIV) 4
using DharmaFECT 3 (Dharmacon) according to the manufac-
turer’s instructions. Quantification of the respective mRNA
knockdown was performed by qRT-PCR. Quantification of
protein knockdown was performed by FACS analysis.
Silencing of S1pr2 by retroviral transduction of shRNA
constructs was done by using phoenix helper-free retrovirus
producer lines with pSIR delta HRCG U6 for the generation of
helper-free retroviruses as described below [55]. The following
shRNA construct targeting S1pr2 mRNA transcript was used:
ACCAAGGAGACGCTGGACATG [56]. Empty vector was used as
control. Quantification of the respective mRNA knockdown was
performed by qRT-PCR. Quantification of protein knockdown
was performed by FACS analysis.
Recombinant protein Nogo-A-D20 (rat aa544-725) was purified
as described previously [12]. Briefly, BL21/DE3 Escherichia coli
were transformed with the pET28 expression vector (Novagen)
containing His-/T7- or His-/HA-tagged Nogo-A-D20 and
cultured at 37uC to reach an OD of 0.6 AU. Protein expression
was induced by addition of 1 M IPTG for 2 h at 30uC. Fusion
proteins were purified using Co2+-Talon Metal Affinity Resin
(Takara Bio Inc.). Nogo-A-ext (rat aa1–979) was cloned into the
KpnI and XhoI restriction sites of the pEXPR-IBA5 expression
vector and the recombinant protein was purified from transiently
transfected HEK293T cells using Strep-tactin chromatography
(IBA).
qRT-PCR
RNA was isolated with RNeasy Micro kit (Qiagen). For
synthesis of cDNA we used SuperScript III reverse transcriptase
(Invitrogen). qRT-PCR was done as described before using the
LightCycler 480 System (Roche, [57]). To determine the relative
expression of the target genes Gna12, Gna13, Gnaq, Larg, and S1pr2
we used Tubb1 and Eef1a1 as housekeeping genes. The following
primers were used: Gna12_FWD: 59-CATGCGATGCTGC-
TAAGCTCAC-39, Gna12_REV: 59-TGTGTGTTCACTCTG-
GGAGGTG-39; Gna13_FWD: 59-ACTAACCGTGCCTCTT-
CAATGGC-39, Gna13_REV: 59-AGGCACCCAACAAGAAC-
ACACTG-39; Gnaq_FWD: 59-TGGGGACAGGGGAGAG-39,
Gnaq_REV: 59-TGGATTCTCAAAAGCAGACAC-39; S1pr2_FWD:
59-CACAGCCAACAGTCTCCAAA-39, S1pr2_REV: 59-TGTTC-
CAGAACCTTCTCAGGA-39; Larg_FWD: 59-GAATCATCAAGG-
TGAATGG-39, Larg_REV: 59-CTGGTGATTCTCTCCATATTC-
39; Tubb1_FWD: 59-GCAGTGCGGCAACCAGAT-39, Tubb1_
REV: 59-AGTGGGATCAATGCCATGCT-39; Eef1a1_FWD:
59-TCCACTTGGTCGCTTTGCT-39, Eef1a1_REV: 59-CTTC-
TTGTCCACAGCTTTGATGA-39.
All samples were analyzed in triplicates. Melting curve analysis
of PCR products followed by gel electrophoresis was performed to
verify amplicons.
Antibodies and Pharmacological Blockers
The following primary antibodies were used: b Tubulin
(Chemicon, MAB3408; 1:1,000), bIII Tubulin (Promega,
G712A; 1:1,000), b-Actin (Sigma, A5441; 1:1,000), BrdU (AbD
Serotec, function-blocking experiments: 5 mg/ml), DAPI (Invitro-
gen, D1306, 1:1,000), EEA1 (Cell Signaling, 2411; 1:100),
GAPDH (Abcam, ab8245; 1:20,000), HA (Roche, 11867423001,
1:200), His (Santa Cruz, sc-804, 1:500), Pan-CDH (Abcam,
ab6528; 1:1,000), Nogo-A (1:10,000, [58]), Nogo-A (Rb173A/
Laura, 1:200), Nogo-A/B (Bianca, Rb1, 1: 20,000, [12]),
Phalloidin-Alexa488 (Invitrogen; 1:500), RhoA (Cell Signaling,
2117; 1:1,000), S1PR2 (Imgenex, IMG-6135A; 1:250), S1PR2
(AbD Serotec custom made HuCAL antibody AbD14533.1
addressing extracellular S1PR2 ECL2; WB 1:1,000; IHC 1:100;
TEM 1:100), S1PR2 (Santa Cruz, sc-365589; 1:500), S1PR5
(Abcam, ab13130; 1:500; function-blocking experiments: 5 mg/
ml), sphingosine 1-phosphate (Funakoshi, 274594052; function-
blocking experiments: 5 mg/ml), Ubiquitin (Enzo Life Sciences,
UWO150; 1:1,000).
The following secondary antibodies were used: Alexa488-
conjugated goat anti-mouse IgG (Invitrogen; 1:1,000), Alexa488-
conjugated goat anti-rabbit IgG (Invitrogen; 1:1,000), Alexa488-
conjugated goat anti-rat IgG (Invitrogen; 1:1,000), Biotin SP-
conjugated AffiniPure goat anti-rabbit IgG (Jackson ImmunoR-
esearch Laboratories; 1:250), Biotin SP-conjugated AffiniPure goat
anti-human IgG F(ab9)2 fragment specific (Jackson ImmunoR-
esearch Laboratories; 1:250), Cy3-conjugated Streptavidin (Jack-
son ImmunoResearch Laboratories; 1:500), Cy5 goat anti-rabbit
(Invitrogen; 1:500), FITC-conjugated goat anti-human IgG (Fab
specific; AbD Serotec), HRP-conjugated goat anti-human IgG
(Fab specific; AbD Serotec), HRP-conjugated goat anti-rabbit IgG
(Fab specific; Amersham), HRP-conjugated goat anti-mouse IgG
(Fab specific; Amersham),
The following pharmacological blockers used in this study have
been dissolved according to the manufacturer’s instructions: W146
(Avanti Polar Lipids), VPC-23019 (Avanti Polar Lipids), JTE-013
(Tocris Bioscience), FTY-720 (Cayman Chemical), and DHS
(Enzo Life Sciences). Nogo-66 was purchased from R&D Systems.
Sphingosine 1-phosphate and Aggrecan were purchased from
Sigma.
Binding Assays
Immobilization-based binding assays were performed on an
Octet Red Instrument (forte´BIO). Recombinant S1PR2 and
control membrane preparations (Millipore) were immobilized on
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amine-reactive biosensors (25 mg/ml; forte´O) in HBSN running
buffer (BIAcore) supplemented with 10 mM MgCl2. Nogo-A-ext
protein was serially diluted and allowed to bind the saturated
biosensor tips for 15 min at 1,000 rpm at 30uC. For experiments
including S1P, 1 mM S1P was added together with Nogo-A-ext.
Methanol was used as vehicle control. The binding response was
normalized for baselines differences between runs and binding
affinities (KD) were calculated from a nonlinear fit according to the
double-reference subtraction method in GraphPad Prism5
(GraphPad software). Data shown are the average of three to five
experiments per condition.
Microscale thermophoresis ligand binding measurements
were performed using a Nanotemper Monolith NT.115 (Nano
Temper technologies) as previously described [59–60]. Briefly,
recombinant Nogo-A-D20 was fluorescently labeled using
the Amine Reactive Protein labeling kit RED (L001, Nano
Temper technologies). The N-terminus and individual ECLs of
S1PR2 were synthesized as peptides (JPT Peptide Technologies,
sequences: N-terminus, MGGLYSEYLNPEKVQEHYNYT-
KETLDMQETPSRK; ECL1, LSGHVTLSLTPVQW; ECL2,
NCLNQLEACSTVLPLYAKHYVL; ECL3, SILLLDSTCPVR-
ACPVLYK; ECL1-scrambled negative control, VGLSQV-
WTSLPTLH). A constant concentration of Nogo-A-D20
(,40 nM) was incubated with the different serially diluted
peptides in PBS containing 0.025% Tween-20 at pH 7.4. 3–5 ml
of each sample was loaded into a hydrophilic glass capillary (K004,
Nano Temper technologies) and thermophoresis analysis was
performed (LED 60%, IR Laser 20%) [59,60]. MST data were
normalized for baseline differences between runs and KD values
were calculated using non-linear regression assuming a Hill
coefficient of 1.0 (GraphPad Prism).
Immunoprecipitation was performed with Nogo-A-D20 and
S1PR2 membrane preparations using the His Protein Interaction
Pull-Down kit following the manufacturer’s instructions (Pierce).
Heat-inactivated Nogo-A-D20 was used as control.
Co-immunoprecipitation was done using whole mouse brain
tissue from P10 Nogo-A2/2, S1PR22/2, and WT mice. Briefly,
tissue was lysed with RIPA buffer (50 mM Tris-HCl [pH 7.2],
150 mM NaCl, 0.1% SDS, 0.5% Na.Deoxycholate, 1% NP-40)
containing cOmplete Mini EDTA-free protease inhibitor cocktail
tablets (Roche). Co-Immunoprecipitation was performed using the
Pierce Co-IP Kit (Pierce 26149) according to the manufacturer’s
instructions.
In Vitro Bioassays
3T3 fibroblast spreading assays and P5-8 cerebellar granule
neurons neurite outgrowth assays were performed as described
previously [12]. Briefly, four-well plates (Greiner) were coated
with 40 pmol/cm2 Nogo-A-D20 or 5 mg/cm2 myelin at 4uC
overnight. Nogo-66 Fc was used at a concentration of 500 nM
and Aggrecan at 1,000 ng/ml. In outgrowth experiments, wells
were precoated with 0.3 mg/ml for 1 h at 37uC before addition
of the different substrates. 3T3 cells were plated at 7,000 cells
per cm2 for 1 h at 37uC and 5% CO2, fixed with 4%
paraformaldehyde (PFA) and stained with Phalloidin-Alexa-488.
Mouse P5-8 cerebellar granule neurons were plated at 7.56104
cells per cm2, cultured for 24 h at 37uC and 5% CO2, fixed with
4% PFA and stained with anti-bIII tubulin. Each experiment
was performed at least three times in four replicate wells.
Spreading was quantified manually in a blinded manner and
mean neurite length was quantified using the MetaMorph
software (Molecular Devices). The mean neurite length is
referred to as the mean total length of all neurites per cell.
3T3 cells were classified as spread cells if they bear at least two
lammelipodial processes longer than one cell body diameter.
Round cells were classified as non-spread. Data were normalized
to baseline and plotted as average 6 standard error of the mean
(SEM). Cells were imaged with a Leica DM5500B microscope
equipped with HCX PL FL Dry 106/0.3 and 206/0.5
objectives in a semi-automated way. Statistical analysis was
performed in GraphPad Prism5 using a one-way ANOVA test
followed by a Bonferroni post hoc test or by using an unpaired
Student’s t-test. All inhibitors were used at a concentration of
100 nM if not elsewhere specified.
Internalization Assays and Flow Cytometry Analysis
Plasma membranes of 3T3 cells were prepared as described
before [61] and after treatment with 1 mM T7-tagged Nogo-A-
D20. Nogo-A-D20 internalization assays were performed as
described previously after treatment of 3T3 cells with 1 mM HA-
tagged Nogo-A-D20 [22]. Briefly, 3T3 cells were incubated with
1 mM Nogo-A-D20 for 1 h on ice (pulse) and subsequently chased
for 15 and 30 min at 37uC. Flow cytometry-based quantification
of S1PR2, G13, and LARG expression on 3T3 cells and CGNs,
respectively, was done in a BD FACSCalibur.
Ubiquitination Assay
3T3 cells were starved in serum-free medium for 24 h. 1 mM
S1P or Nogo-A-D20, respectively, was added to 3T3 cells for
60 min. Isolation of ubiquitinated protein fractions was done using
UbiCapture-Q (Enzo Life Sciences). Finally, western blot analysis
was performed to detect S1PR2 and ubiquitin.
RhoA Pulldown
3T3 cells were serum-starved overnight and treated for 20 min
with 1 mM Nogo-A-D20 or heat-inactivated Nogo-A-D20
control protein. Pulldown of activated RhoA-GTP was subse-
quently performed using the RhoA Activation Assay Biochem
Kit according to the manufacturer’s instructions (Cytoskeleton,
Inc.).
S1P Quantification
3T3 cells or CGNs were cultured up to 80%–85% confluence in
15 cm dishes and serum starved for 24 h prior to the experiment.
Nogo-A-D20 was added to the cells at a concentration of 1 mM.
After 15, 30, and 60 min, 3T3 cells and CGNs were lysed in
400 ml lysis buffer (20 mM PIPES, 150 mM NaCl, 1 mM EGTA,
1% v/v Triton X-100, 1.5 mM MgCl2, pH 7.4). Lysates were
frozen immediately at 280uC. Protein concentration was mea-
sured and cell lysates (1:10 in delipidized human sera) were
analyzed with the Echelon S1P ELISA kit according to the
manufacturer’s instruction. Serum free cell culture medium was
directly diluted 1:10 in delipidized human serum and subsequently
analyzed with the S1P ELISA kit.
Immunohistochemistry
Immunohistochemistry was performed as described previously
[62]. Briefly, animals were transcardially perfused with Ringer’s
solution, followed by 4% PFA. Prior to staining, sections were
treated with 0.2% glutaraldehyde and 50 mM Tris-glycine
(pH 8.0). After antigen retrieval via microwaving three times for
10 s at 600 W, the sections were treated with Kryofix (Merck) for
10 min followed by 0.3% Triton X-100 for 10 min. S1PR2 was
detected with AbD14533.1 and corresponding secondary anti-
bodies.
3T3 cells and CGNs were fixed with 4% PFA for 15 min,
washed, and permeabilized with 0.1% Triton X-100. After
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blocking with 2% goat serum, cells were first incubated with
AbD14533.1 and detected using Cy3-conjugated Streptavidin.
For cell surface immunocytochemical detection of S1PR2, 3T3
cells were incubated with 50 mg/ml AbD14533.1 in serum-free
medium containing 0.02% sodium azide for 20 min on ice. Cells
were washed and fixed with 0.5% PFA. After blocking (4% fetal
calf serum, 2% horse serum, 0.1% cold water fish gelatine, 0.1%
casein) on ice, cells were first incubated with biotinylated goat anti-
human IgG, biotinylated rabbit anti-goat, and, finally, with Cy3-
conjugated Streptavidin.
Electrophysiology
Hippocampus. Acute hippocampal slices were prepared from
40–60 day old (P40–P60) WT C57BL/6 mice or Nogo-A2/2 mice
according to standard procedures. In brief, mice were anesthetized
and decapitated; the brain was quickly transferred into ice-cold
carbogenated (95% O2, 5% CO2) artificial cerebrospinal fluid
(ACSF). Hippocampi were cut with a vibratome (400 mm; VT
1000S; Leica). The ACSF used for electrophysiological recordings
contained 125 mMNaCl, 2 mMKCl, 1.25 mMNaH2PO4, 1 mM
MgCl2, 26 mM NaHCO3, 2 mM CaCl2, 25 mM glucose.
Recordings were done at 32uC.
Blockade of S1PR2 was achieved by incubation of acute slices
with JTE-013, blockade of S1PR1, 3, 4, 5 with FTY-720 and
blockade of S1PR1, 3 with VPC-23019, respectively. The
inhibitors were dissolved in DMSO and freshly added at a final
concentration of 5 mM, 1 mM, and 0.1 mM, respectively, to the
carbogenated ACSF. The DMSO overall concentration in the
ACSF was kept at 0.01%. As control DMSO alone was added. In
order to compare the data with previous experiments silicon
tubing was used, and pre-washed with ACSF containing BSA
(0.1 mg/ml). The slices were pre-incubated for 1 h (or 10 min for
the experiments in which JTE-013 and 11c7 were combined) with
the inhibitor or DMSO as control in an incubation chamber
maintaining a constant flow of the solution. During the
experiments the inhibitor was also around. For the electrophys-
iological recordings, the perfusion rate in the recording chamber
was constantly kept at 1.5 ml/min.
After placing the slices in a submerged recording chamber field,
excitatory postsynaptic potentials (fEPSPs) were recorded in the
stratum radiatum of the CA1 region with a glass micropipette
(resistance 3–15 MV filled with 3 M NaCl at a depth of,100 mm.
Monopolar tungsten electrodes were used for stimulating the
Schaffer collaterals at a frequency of 0.1 Hz. Stimulation was set
to elicit a fEPSP with a slope of,40%–50% of maximum for LTP
recordings. After 20 min baseline stimulation LTP was induced by
applying theta-burst stimulation (TBS), in which a burst consisted
of four pulses at 100 Hz. These were repeated 10 times in 200 ms
intervals (5 Hz). Three such trains were used to induce LTP at
0.1 Hz. Basic synaptic transmission and presynaptic properties
were analyzed via I/O measurements and paired pulse facilitation.
The I/O measurements were performed either by application of a
defined value of current (25–250 mA in steps of 25 mA) or
by adjusting the stimulus intensity to a certain current eliciting a
fiber volley (FV) of desired voltage. Paired pulse facilitation
was performed by applying a pair of two stimuli in different
inter-stimulus-intervals (ISIs), ranging from 10, 20, 40, and 80
to 160 ms. Data were collected, stored, and analyzed with
LABVIEW software (National Instruments). The initial slope of
fEPSPs elicited by stimulation of the Schaffer collaterals was
measured over time, normalized to baseline, and plotted as
average 6 SEM.
Motor cortex. For LTP measurements in the motor cortex
[11], coronal slices containing the forelimb are of M1 (1–2 mm
anterior to the bregma [63]), and were prepared from adult
Sprague Dawley rats (180–220 g). JTE-013 concentrations were
used according to protocols used for hippocampal slices and added
to the ACSF: 126 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4,
26 mM NaHCO3, 1 mM MgSO4, 2 mM CaCl2, and 10 mM
glucose, bubbled with a 95% O2, 5% CO2 mixture at 3360.5uC).
To allow optimal JTE-013 penetration, responses were recorded
from the slice superface of layer II/III within M1. Basic synaptic
transmission was analyzed with I/O analysis. I/O measurements
were conducted by applying a value of current, which elicited a
minimal (threshold) evoked response (0.2–0.3 mV). I/O curves
were obtained by averaging field potential peak amplitudes of
three responses to stimuli of two, three, four, and five times the
threshold response. To elicit the maximum amplitude that could
be evoked, we used a stimulation intensity of 256 threshold
[64,65]. For baseline measurements, stimulus intensity was
adjusted to produce responses 40%–50% of the maximum
amplitude. For data analysis, we computed the amplitude of the
field potential response because it serves as a measure of the
population excitatory synaptic response [65], reflects a monosyn-
aptic current sink [66], and correlates well with the intracellular
excitatory postsynaptic response evoked in this pathway [67].
Measurement of the field potential slope, as routinely used, e.g., in
the hippocampus, has not been used for neocortical field potential
responses due to the interference of the response’s initial part by
variable nonsynaptic components [68]. After 20 min of baseline
stimulation, focal and transient reduction of y-aminobuturic acid-
A (GABA) inhibition at the recording site was produced by
applying bicuculline methiodide (3.3 mM, Tocris Bioscience) from
a micropipette by touching the tip to the slice surface within
100 mm of the recording microelectrode for 15–60 s. The pipette
was removed when the amplitude of test responses increased 50%–
100% of baseline [66]. Immediately after bicuculline application,
LTP was attempted by delivering TBS at double baseline
stimulation intensity. LTP induction was attempted by using
TBS, which consisted of 10 trains of stimuli at 5 Hz. Each train
was composed of four pulses at 100 Hz. This sequence was
delivered every 10 s for a total of five presentations. LTP was
recorded for at least 20 min after it reached a stable plateau. TBS
was induced until responses were saturated. Pathways were
considered saturated if the difference between two subsequent
states of LTP were not significantly different [68]. Maximum LTP
was calculated as a percentage of baseline, plotted as average 6
SEM and analyzed by a Student’s t-test. Data were collected,
stored, and analyzed with LABVIEW (National Instruments) and
MATLAB (MathWorks) software.
Supporting Information
Figure S1 S1PR2 expression in 3T3 fibroblasts and
immature cerebellar granule cells. (A,B) Immunofluores-
cence staining of 3T3 cells (A) and P8 cerebellar granule cell with
neurite and growth cone (B) for S1PR2, nuclei (DAPI), and F-
Actin (Phalloidin-Alexa488). Scale bars: 50 mm.
(TIF)
Figure S2 Purity of plasma membrane preparations
and specificity of custom-made S1PR2 antibody
Ab14533.1. (A) Western Blot analysis of 3T3 plasma membrane
preparations reveals non-detectable amount of EEA1-positive
endosomal membranes, but high content of Pan-CDH-positive
plasma membrane fractions compared to whole cell lysates. MP,
membrane preparations; L, whole cell lysate. (B) Ab14533.1
detects S1PR2 in whole brain tissue extracts. Protein expression is
higher in embryonic stages (E11.5, E14.5) than in adult animals.
S1PR2 Is a Receptor for Nogo-A
PLOS Biology | www.plosbiology.org 14 January 2014 | Volume 12 | Issue 1 | e1001763
S1PR2 signals are strongly decreased when challenged in a
competition assay with the immunogenic peptide (P). (C)
Immunohistochemical analysis of S1PR2 in the adult motor
cortex (compare to Figure 1E and 1F) shows abolished S1PR2
detection using the same peptide competition assay.
(TIF)
Figure S3 Blockade of S1PR1, 3, 4, and/or 5 has no
effect on Nogo-A-D20-mediated cell spreading inhibi-
tion. (A) 3T3 fibroblasts were plated on different concentrations
of a Nogo-A-D20 substrate in the presence of increasing
concentrations of JTE-013 versus vehicle (DMSO). (B) 3T3
fibroblasts were plated on a Nogo-A-D20 substrate in the presence
of the following pharmacological inhibitors: W146 for S1PR1,
VPC-23019 for S1PR1 and 3, and FTY-720 for S1PR1, 3, 4, and
5. DMSO was used as control. A function-blocking anti-S1PR5
antibody had no effect on Nogo-A-D20-induced inhibition when
compared to anti-BrdU control. (C) 3T3 fibroblasts were plated on
a Nogo-A-D20 substrate in the presence of JTE-013 in different
combinations with VPC-23019, W146 and/or anti-S1PR5.
DMSO was used as control. Data shown are means 6 SEM
(n=3–4 experiments; *p,0.05, **p,0.01, ***p,0.001).
(TIF)
Figure S4 Knockdown efficacy of S1PR2, Gq, G12, G13,
and LARG. (A) Quantitative RT-PCR analysis of S1PR2
expression in 3T3 cells stably expressing S1pr2 shRNA (sh-S1pr2)
versus control vector (sh-Vec) revealed an ,93% knockdown. (B)
FACS analysis of S1PR2 expression in 3T3 cells stably expressing
sh-S1pr2 or sh-Vec using the Ab14533.1 antibody. (C) Quantita-
tive RT-PCR analysis of 3T3 cells treated with siRNA targeting
Gq, G12, G13, or Larg for 72 h. Scrambled siRNA (ctrl) was used as
control. Relative quantification of knockdown efficacy: G12
(,77%), G13 (,78%), Gq (,79%), and Larg (83%). (D) FACS
analysis of G13 expression in G13 versus ctrl siRNA-treated 3T3
cells. (E) Quantitative RT-PCR analysis of E19 rat cortical
neurons treated at DIV4 with siRNA targeting G12 or G13 for 72 h.
Scrambled siRNA (ctrl) was used as control. Relative quantifica-
tion of knock-down efficacy: G12 (39%), G13 (42%). (F) FACS
analysis of G13 expression in G13 versus ctrl siRNA-treated E19
cortical neurons. (G) FACS analysis of LARG expression in Larg
versus ctrl siRNA-treated 3T3 cells. Histograms from one
representative experiment are shown. Data shown are means 6
SEM (n=3 experiments).
(TIF)
Figure S5 S1PR2 blockade has no effect on Nogo-66- and
Aggrecan-mediated inhibition of neurite outgrowth. (A,B)
Mean neurite length quantification of P5–8 CGNs treated with
JTE-013 or DMSO and plated on a Nogo-66 (A) or Aggrecan (B)
versus ctrl (PLL) substrate. Data shown are means 6 SEM (n=4
replicates).
(TIF)
Figure S6 Pharmacological inhibition of S1PR1 and 3 or
S1PR1, 3, 4, and 5 does not increase hippocampal LTP.
(A,B) WT hippocampal slices were treated with VPC-23019 (n=7)
(A) or FTY-720 (n=8) (B) to block S1PR1 and 3 or S1PR1, 3, 4
and 5, respectively. DMSO was used as control in (A) (n=11) and
(B) (n=9). No significant differences in LTP could be observed
between VPC-23019, FTY-720 and DMSO treatment. (C) PPF
revealed no alterations in VPC-23019- (n=5) or FTY-720- (n=7)
versus DMSO- (n=7) treated slices. (D) No significant difference
in LTP could be observed in S1PR22/2 (n=11) versus WT
(n=12) mice. (E) Input-output strength revealed no alterations in
S1PR22/2 (n=8) versus WT (n=12) mice. (F) PPF revealed no
alterations in S1PR22/2 (n=11) versus WT (n=13) mice. (G) No
significant difference in hippocampal long-term depression (LTD)
could be observed between JTE-013- (n=4) versus DMSO- (n=5)
treated WT slices. Arrows indicate the onset of theta-burst (A,B,D)
or low frequency (G) stimulation. Data shown are means 6 SEM.
n indicates the number of mice used.
(TIF)
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